Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Mesothelioma, Malignant 2Hearing Loss 2Testicular Neoplasms 1Seminoma 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Ototoxicity 1Optic Nerve Glioma 1Oligodendroglioma 1Necrosis 1Mesothelioma 1Medulloblastoma 1Gastrointestinal Neoplasms 1Familial ependymoma 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Astrocytoma 1Appendiceal Neoplasms 1

Interventions

sodium thiosulfate 1Platinum 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-12 Subunit p35 1Hearing 1Cisplatin 1CTLA-4 Antigen 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Seminoma × sodium thiosulfate × Clear all
NCT07218913 2026-04-17

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

City of Hope Medical Center

Phase 1 Recruiting
44 enrolled
Genitourinary

Testicular Neoplasms, Seminoma, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡